{"component": "clause", "props": {"groups": [{"snippet_links": [{"key": "the-parties-recognize", "type": "clause", "offset": [0, 21]}, {"key": "general-capabilities", "type": "clause", "offset": [58, 78]}, {"key": "adimab-platform-technology", "type": "clause", "offset": [86, 112]}, {"key": "in-connection", "type": "definition", "offset": [114, 127]}, {"key": "and-provided-that", "type": "clause", "offset": [139, 156]}, {"key": "the-target", "type": "clause", "offset": [232, 242]}, {"key": "sequence-information", "type": "definition", "offset": [270, 290]}, {"key": "right-to-disclose", "type": "clause", "offset": [354, 371]}, {"key": "for-clarity", "type": "clause", "offset": [445, 456]}, {"key": "the-article", "type": "definition", "offset": [487, 498]}], "size": 4, "samples": [{"hash": "7hlbq9lfKYL", "uri": "/contracts/7hlbq9lfKYL#certain-data", "label": "Option and License Agreement", "score": 31.3408622742, "published": true}, {"hash": "kBbZ7UPK36x", "uri": "/contracts/kBbZ7UPK36x#certain-data", "label": "Option and License Agreement (Arsanis, Inc.)", "score": 28.8001365662, "published": true}, {"hash": "iOA4NQPhoD7", "uri": "/contracts/iOA4NQPhoD7#certain-data", "label": "Option and License Agreement (Arsanis, Inc.)", "score": 28.7180023193, "published": true}], "snippet": "The Parties recognize the need for Adimab to disclose the general capabilities of the Adimab Platform Technology. In connection therewith, and provided that Adimab does not disclose the identity of Arsanis, any Adimab RSV Antibody, the target thereof (i.e., RSV) or any Sequence information as to the CDRs of Adimab RSV Antibodies, Adimab shall have the right to disclose generally Adimab RSV Antibody attributes, including the following: [**]. For clarity, Adimab has already published the article by \u2587\u2587\u2587\u2587\u2587\u2587 et al., entitled \u201cRapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors\u201d, Sci Immunol., Vol. 1(6), December 16, 2016 (Epublished December 9, 2016), which article includes the sequences of certain Adimab RSV Antibodies.", "hash": "96d82458ed5c5524f8a5889a6a93f455", "id": 1}, {"snippet_links": [{"key": "article-8", "type": "definition", "offset": [21, 30]}, {"key": "the-applicable", "type": "clause", "offset": [89, 103]}, {"key": "program-target", "type": "definition", "offset": [115, 129]}, {"key": "class-of", "type": "definition", "offset": [144, 152]}, {"key": "selected-antibody", "type": "definition", "offset": [247, 264]}, {"key": "in-order-to", "type": "clause", "offset": [266, 277]}, {"key": "general-capabilities", "type": "clause", "offset": [291, 311]}, {"key": "to-disclose", "type": "definition", "offset": [377, 388]}], "size": 2, "samples": [{"hash": "hARjuTQMGM4", "uri": "/contracts/hARjuTQMGM4#certain-data", "label": "Collaboration Agreement (Mersana Therapeutics, Inc.)", "score": 28.414100647, "published": true}, {"hash": "ex9b4q7MAZv", "uri": "/contracts/ex9b4q7MAZv#certain-data", "label": "Collaboration Agreement (Mersana Therapeutics, Inc.)", "score": 28.2060241699, "published": true}], "snippet": "Notwithstanding this ARTICLE 8, without disclosing Mersana\u2019s identity or the identity of the applicable Validation Program Target (although the class of protein of the applicable Validation Program Target may be disclosed), or the sequence of any Selected Antibody, in order to describe the general capabilities and performance of the Adimab platform, Adimab shall be entitled to disclose generally [***], including the following: (a) [***]; (b) [***]; (c) [***]; (d) [***].", "hash": "db32b771cacbedc3450b644d62ef9e17", "id": 2}, {"snippet_links": [{"key": "article-6", "type": "clause", "offset": [21, 30]}, {"key": "the-target", "type": "clause", "offset": [164, 174]}, {"key": "class-of", "type": "definition", "offset": [296, 304]}, {"key": "the-family", "type": "clause", "offset": [336, 346]}, {"key": "program-antibody", "type": "definition", "offset": [390, 406]}, {"key": "in-order-to", "type": "clause", "offset": [408, 419]}, {"key": "general-capabilities", "type": "clause", "offset": [433, 453]}, {"key": "to-disclose", "type": "definition", "offset": [519, 530]}, {"key": "distribution-of", "type": "clause", "offset": [710, 725]}], "size": 2, "samples": [{"hash": "addxHX0WxWZ", "uri": "/contracts/addxHX0WxWZ#certain-data", "label": "Development and Option Agreement (Surface Oncology, Inc.)", "score": 29.2217655182, "published": true}, {"hash": "5BOrsbbpGxe", "uri": "/contracts/5BOrsbbpGxe#certain-data", "label": "Development and Option Agreement (Surface Oncology, Inc.)", "score": 28.8767967224, "published": true}], "snippet": "Notwithstanding this Article 6, without disclosing Surface\u2019s (or any of its Affiliates\u2019 or licensees\u2019, sublicensees\u2019 or collaborators\u2019) identity or the identity of the Target or the possible indication(s), or information making such identities or indications reasonably discernable (although the class of protein of the Target (but not the family) may be disclosed), or the sequence of any Program Antibody, in order to describe the general capabilities and performance of the Adimab platform, Adimab shall be entitled to disclose generally Program Antibody attributes , including the following: (a) Program Antibody binding affinities (KD), (b) expression range regarding Program Antibodies, and (c) germline distribution of Program Antibodies.", "hash": "187d3ee1222b1171570842d3fe6d98f3", "id": 3}, {"snippet_links": [{"key": "related-data", "type": "definition", "offset": [27, 39]}, {"key": "the-memorandum", "type": "clause", "offset": [52, 66]}, {"key": "based-on", "type": "definition", "offset": [71, 79]}, {"key": "the-company", "type": "definition", "offset": [109, 120]}], "size": 2, "samples": [{"hash": "jz8VNY5lVa2", "uri": "/contracts/jz8VNY5lVa2#certain-data", "label": "Securities Purchase Agreement (Icahn Carl C Et Al)", "score": 18.0, "published": true}, {"hash": "aBXxz5LDe56", "uri": "/contracts/aBXxz5LDe56#certain-data", "label": "Securities Purchase Agreement (Adventrx Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet": "The statistical and market-related data included in the Memorandum are based on or derived from sources that the Company believes to be reliable and accurate.", "hash": "40b07eaf80131d1ef6eb7db37b144ae2", "id": 4}, {"snippet_links": [{"key": "article-6", "type": "clause", "offset": [25, 34]}, {"key": "program-antibody", "type": "definition", "offset": [99, 115]}, {"key": "the-target", "type": "clause", "offset": [175, 185]}, {"key": "class-of", "type": "definition", "offset": [200, 208]}, {"key": "to-disclose", "type": "definition", "offset": [275, 286]}, {"key": "in-addition", "type": "clause", "offset": [333, 344]}, {"key": "responsible-for", "type": "clause", "offset": [518, 533]}, {"key": "no-data", "type": "definition", "offset": [670, 677]}, {"key": "section-67", "type": "clause", "offset": [731, 742]}, {"key": "the-data", "type": "clause", "offset": [826, 834]}, {"key": "to-the-extent", "type": "clause", "offset": [900, 913]}], "size": 2, "samples": [{"hash": "12tCveQBqIV", "uri": "/contracts/12tCveQBqIV#certain-data", "label": "Collaboration Agreement (Merrimack Pharmaceuticals Inc)", "score": 22.8151950836, "published": true}, {"hash": "e6d4vc4efQe", "uri": "/contracts/e6d4vc4efQe#certain-data", "label": "Collaboration Agreement (Merrimack Pharmaceuticals Inc)", "score": 22.5140323639, "published": true}], "snippet": "(a) Notwithstanding this Article 6, without disclosing Merrimack\u2019s identity or the identity of the Program Antibody, other antibodies previously tested by or for Merrimack or the Target (although the class of protein of the Target may be disclosed), Adimab shall be entitled to disclose the following Program Know-How: (i) [**].\n(b) In addition, Merrimack [**] to [**], and [**] to [**] or [**] as [**] by [**] to [**] and [**]. Such data [**] in [**] to [**] by [**]. Any such data that [**] for [**] as [**] will be responsible for [**] of the [**] to [**] as [**] to the [**] or the [**], but is [**] to [**] for [**] and [**]. To be clear, if there is [**] for [**] no data [**] the [**] for data [**] be disclosed pursuant to Section 6.7(a) above. Further, for the sake of clarity, this Section 6.7 does not [**] to [**] the data for [**] described in Section 6.7(a) or 6.7(b) to [**], and [**] to the extent that it is [**].", "hash": "f44881d37bc45580b122567461f1962e", "id": 5}, {"snippet_links": [{"key": "related-data", "type": "definition", "offset": [45, 57]}, {"key": "the-registration-statement", "type": "clause", "offset": [70, 96]}, {"key": "package-and-the-prospectus", "type": "clause", "offset": [121, 147]}, {"key": "based-on", "type": "definition", "offset": [152, 160]}, {"key": "the-company", "type": "definition", "offset": [191, 202]}, {"key": "in-good-faith", "type": "definition", "offset": [218, 231]}], "size": 2, "samples": [{"hash": "cxai4LgiV9Q", "uri": "/contracts/cxai4LgiV9Q#certain-data", "label": "Underwriting Agreement (WhiteHorse Finance, Inc.)", "score": 24.5208759308, "published": true}, {"hash": "2GtRCaMYd9V", "uri": "/contracts/2GtRCaMYd9V#certain-data", "label": "Underwriting Agreement (WhiteHorse Finance, LLC)", "score": 23.9130725861, "published": true}], "snippet": "The statistical, industry-related and market-related data included in the Registration Statement, the General Disclosure Package and the Prospectus are based on or derived from sources which the Company reasonably and in good faith believes are reliable and accurate, and such data agree with the sources from which they are derived.", "hash": "2c28c5f9d434798e43683488f525532b", "id": 6}, {"snippet_links": [{"key": "the-parties-recognize", "type": "clause", "offset": [0, 21]}, {"key": "to-disclose", "type": "definition", "offset": [42, 53]}, {"key": "general-capabilities", "type": "clause", "offset": [58, 78]}, {"key": "adimab-platform-technology", "type": "clause", "offset": [86, 112]}, {"key": "in-connection", "type": "definition", "offset": [114, 127]}, {"key": "article-6", "type": "clause", "offset": [160, 169]}, {"key": "the-target", "type": "clause", "offset": [260, 270]}, {"key": "class-of", "type": "definition", "offset": [285, 293]}, {"key": "program-antibody", "type": "definition", "offset": [375, 391]}, {"key": "program-inventions", "type": "clause", "offset": [472, 490]}, {"key": "distribution-of", "type": "clause", "offset": [627, 642]}, {"key": "development-of", "type": "clause", "offset": [755, 769]}], "size": 2, "samples": [{"hash": "99F1e4n3XqS", "uri": "/contracts/99F1e4n3XqS#certain-data", "label": "Collaboration Agreement (Scholar Rock Holding Corp)", "score": 30.1937026978, "published": true}], "snippet": "The Parties recognize the need for Adimab to disclose the general capabilities of the Adimab Platform Technology. In connection therewith, notwithstanding this Article 6 (Confidentiality; Publicity), without disclosing Scholar Rock\u2019s identity, the identity of the Target (although the class of Target may be disclosed as protein to protein complexes), or the sequence of any Program Antibody, Adimab shall be entitled to disclose generally Program Antibody attributes and Program Inventions, including the following: (a) Program Antibody binding affinities (kD), (b) expression range regarding Program Antibodies, (c) germline distribution of Program Antibodies, (d) Program Antibody format (i.e., monoclonal, \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 bispecific, etc.), and (e) stage of development of Program-Benefited Antibodies.", "hash": "20ed1ff872c5b1113dbb2359b34b3696", "id": 7}, {"snippet_links": [{"key": "article-6", "type": "clause", "offset": [21, 30]}, {"key": "the-target", "type": "clause", "offset": [121, 131]}, {"key": "class-of", "type": "definition", "offset": [146, 154]}, {"key": "program-antibody", "type": "definition", "offset": [219, 235]}, {"key": "in-order-to", "type": "clause", "offset": [237, 248]}, {"key": "general-capabilities", "type": "clause", "offset": [262, 282]}, {"key": "to-disclose", "type": "definition", "offset": [348, 359]}, {"key": "distribution-of", "type": "clause", "offset": [559, 574]}], "size": 2, "samples": [{"hash": "7k9v4YyYw6v", "uri": "/contracts/7k9v4YyYw6v#certain-data", "label": "Collaboration Agreement (Checkpoint Therapeutics, Inc.)", "score": 30.2073917389, "published": true}], "snippet": "Notwithstanding this Article 6 (Confidentiality; Publicity), without disclosing Checkpoint\u2019s identity or the identity of the Target (although the class of protein of the Target may be disclosed), or the sequence of any Program Antibody, in order to describe the general capabilities and performance of the Adimab platform, Adimab shall be entitled to disclose generally Program Antibody attributes and Program Know-How, including the following: (a) Program Antibody binding affinities (KD), (b) expression range regarding Program Antibodies, and (c) germline distribution of Program Antibodies.", "hash": "dd7ce363e2b5d170a2162f51a2aa3201", "id": 8}, {"snippet_links": [{"key": "article-6", "type": "clause", "offset": [21, 30]}, {"key": "the-target", "type": "clause", "offset": [164, 174]}, {"key": "class-of", "type": "definition", "offset": [296, 304]}, {"key": "the-family", "type": "clause", "offset": [336, 346]}, {"key": "program-antibody", "type": "definition", "offset": [390, 406]}, {"key": "in-order-to", "type": "clause", "offset": [408, 419]}, {"key": "general-capabilities", "type": "clause", "offset": [433, 453]}, {"key": "to-disclose", "type": "definition", "offset": [519, 530]}, {"key": "distribution-of", "type": "clause", "offset": [710, 725]}, {"key": "this-exhibit", "type": "definition", "offset": [779, 791]}, {"key": "replaced-with", "type": "clause", "offset": [809, 822]}, {"key": "the-secretary", "type": "clause", "offset": [898, 911]}, {"key": "the-securities-and-exchange-commission", "type": "clause", "offset": [915, 953]}, {"key": "confidential-treatment", "type": "definition", "offset": [992, 1014]}, {"key": "pursuant-to-rule", "type": "clause", "offset": [1015, 1031]}, {"key": "securities-act-of-1933", "type": "clause", "offset": [1058, 1080]}, {"key": "as-amended", "type": "definition", "offset": [1082, 1092]}], "size": 1, "samples": [{"hash": "8OlHmvO4t7P", "uri": "/contracts/8OlHmvO4t7P#certain-data", "label": "Development and Option Agreement (Surface Oncology, Inc.)", "score": 29.8651599884, "published": true}], "snippet": "Notwithstanding this Article 6, without disclosing Surface\u2019s (or any of its Affiliates\u2019 or licensees\u2019, sublicensees\u2019 or collaborators\u2019) identity or the identity of the Target or the possible indication(s), or information making such identities or indications reasonably discernable (although the class of protein of the Target (but not the family) may be disclosed), or the sequence of any Program Antibody, in order to describe the general capabilities and performance of the Adimab platform, Adimab shall be entitled to disclose generally Program Antibody attributes , including the following: (a) Program Antibody binding affinities (KD), (b) expression range regarding Program Antibodies, and (c) germline distribution of Program Antibodies. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH \u201c[***]\u201d. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.", "hash": "c883da62a79940cac6837f3b69d759a9", "id": 9}, {"snippet_links": [{"key": "article-6", "type": "clause", "offset": [21, 30]}, {"key": "class-of", "type": "definition", "offset": [95, 103]}, {"key": "to-disclose", "type": "definition", "offset": [195, 206]}, {"key": "program-antibody", "type": "definition", "offset": [221, 237]}, {"key": "distribution-of", "type": "clause", "offset": [362, 377]}, {"key": "prior-written-approval", "type": "definition", "offset": [421, 443]}, {"key": "in-vitro", "type": "definition", "offset": [486, 494]}, {"key": "in-no-event-shall", "type": "clause", "offset": [507, 524]}, {"key": "provide-information", "type": "clause", "offset": [561, 580]}], "size": 1, "samples": [{"hash": "1m2qLV03OTS", "uri": "/contracts/1m2qLV03OTS#certain-data", "label": "Collaboration Agreement (Alector, Inc.)", "score": 29.7775497437, "published": true}], "snippet": "Notwithstanding this Article 6, without disclosing Alector\u2019s identity, the identity, nature or class of any Target, or the potential indications or class of indications, Adimab shall be entitled to disclose the following Program Antibody attributes: (a) Program Antibody binding affinities (1(D), (b) expression range regarding Program Antibodies, (c) germ line distribution of Program Antibodies, and (d) with Alector\u2019s prior written approval, preclinical data in mammalian-cell based in vitro assays, and in no event shall Alector be required to correlate or provide information that correlates such data to any antibody sequences.", "hash": "d2547a46dfba0232efcd382b861d82c4", "id": 10}], "next_curs": "ClUST2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjELEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IhVjZXJ0YWluLWRhdGEjMDAwMDAwMGEMogECZW4YACAA", "clause": {"title": "Certain Data", "parents": [["confidentiality-publicity", "Confidentiality Publicity"], ["late-payments", "Late Payments"], ["representations-and-warranties-of-seller", "REPRESENTATIONS AND WARRANTIES OF SELLER"], ["financial-matters", "Financial Matters"], ["representations-and-warranties", "Representations and Warranties"]], "children": [["material-breach", "Material Breach"], ["survival-in-all-cases", "Survival in All Cases"], ["term", "Term"], ["survival-of-sublicenses", "Survival of Sublicenses"], ["disclaimer-of-warranties", "DISCLAIMER OF WARRANTIES"]], "size": 31, "id": "certain-data", "related": [["certain-records", "Certain Records", "Certain Records"], ["treatment-of-certain-confidential-information", "Treatment of Certain Confidential Information", "Treatment of Certain Confidential Information"], ["certain-disclosures", "Certain Disclosures", "Certain Disclosures"], ["use-of-fiiocs-and-fscs-name", "Use of FIIOC\u2019s and FSC's Name", "Use of FIIOC\u2019s and FSC's Name"], ["certain-matters", "Certain Matters", "Certain Matters"]], "related_snippets": [], "updated": "2026-09-05T05:44:37+00:00", "also_ask": [], "drafting_tip": "", "explanation": "The 'Certain Data' clause defines specific categories or types of data that are subject to particular terms within an agreement. Typically, this clause identifies which data is covered, such as personal information, confidential business data, or technical information, and may outline how this data should be handled, protected, or shared between parties. By clearly specifying what constitutes 'Certain Data,' the clause ensures both parties understand their obligations regarding the treatment of sensitive or important information, thereby reducing ambiguity and mitigating the risk of data misuse or unauthorized disclosure."}, "json": true, "cursor": ""}}